Christian Roesel1, Kato Kambartel2, Uldis Kopeika1, Arvids Berzins1, Thomas Voshaar2, Thomas Krbek1
1Department for Thoracic Surgery, Lung Cancer Center, Bethanien Hospital, Moers, Germany
2Department of Pneumology and Allergy, Lung Cancer Center, Bethanien Hospital, Moers, Germany
Tóm tắt
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung carcinoma with a poor prognosis and poor response to chemotherapy and radiotherapy. A previous study reported that psc expresses high levels of PD-L1, suggesting the potential efficacy of immune checkpoint inhibitors in these tumours. We report 2 cases of patients with a lung sarcomatoid carcinoma. Both patients initially underwent curative lung resection, but developed early recurrent disease. Because PD-L1 was highly expressed in the tumour cells, we initiated therapy with nivolumab, which showed good efficacy, almost complete radiologic tumour remission, and a remarkable improvement in the condition of those patients. Immune checkpoint inhibitors targeting PD-1 might be a valuable therapy option for PSCS.
